Premium 5 Ltd., the Leading Canadian Cannabis Concentrate Products Company Announces EBITDA Positive Q3 2020 Financial Results

EDMONTON, Alberta–(BUSINESS WIRE)–Premium 5 Ltd. (“Premium 5” or the “Company”) today announced financial results for its fiscal 2020 third quarter ending September 30th, 2020. Premium 5 has successfully navigated complex product development and regulatory challenges to offer a portfolio of innovative concentrate products. Currently, the Company has 22 SKU offerings across Canada. For the recreational…

Lygos Announces the Launch of Lygos CBx™, a New Low-Cost, Industrial-Scale Cannabinoid Production Company

BERKELEY, Calif.–(BUSINESS WIRE)–Lygos, Inc., a vertically integrated provider of safe and sustainable specialty ingredients, today announced the launch of Lygos CBx, a Lygos company and new website focused on delivering a wide range of high-quality, pure and sustainable non-plant-based cannabinoids. Lygos CBx is a result of the combination of Librede, the recently acquired NIH-funded biosynthetic…

United States Plant Protein Business and Investment Opportunities Report 2020 & Forecast to 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “United States Plant Protein Business and Investment Opportunities (2018-2027) Insight Series – White Space/Gap Analysis, Product Strategy, Innovation and Brand Share Analysis, Competitive Landscape, Market Size Across 50+ Segments – Updated in Q3, 2020” report has been added to ResearchAndMarkets.com’s offering. Plant protein industry is expected to continue to grow in United States…

United States CBD Top Brands & Pricing Report 2020: Topicals are Increasing in the Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CBD Top Brands & Pricing Report: Topicals are Increasing in the US Market” report has been added to ResearchAndMarkets.com’s offering. If you are interested in the US market then this is the report for you. As well as gaining valuable data around brand engagement with product categories, and added and discontinued products, you’ll…

CBD Top Brands & Pricing Report: Other Cannabinoids Enter the UK Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CBD Top Brands & Pricing Report: Other Cannabinoids Enter the UK Market” report has been added to ResearchAndMarkets.com’s offering. There has been a significant number of products that have been introduced in the CBD market during this third quarter of 2020, with oils and topicals continuing to take the lead. The UK market…

$40+ Billion CBD Consumer Health Market – Global Outlook Report 2019-2020 & Forecast to 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CBD Consumer Health – Global Market Outlook (2019-2027)” report has been added to ResearchAndMarkets.com’s offering. Global CBD Consumer Health Market accounted for $7.89 billion in 2019 and is expected to reach $40.2 billion by 2027, growing at a CAGR of 22.6% during the forecast period. Growing legalization of cannabis-based CBD products, rise in…

Organigram Confirms Additional $2.5 Million Investment in Hyasynth Biologicals Inc. as Biosynthesis Pioneer Completes First Milestone Linked to First Sale of Commercial Product and Announces Executive Changes

MONCTON, New Brunswick–(BUSINESS WIRE)–As an early investor in biosynthesis, Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce it has funded an additional $2.5 million investment in Hyasynth Biologicals Inc. (“Hyasynth”), a private biotechnology company and pioneer…

GrowerIQ Announces Partnership with High North Labs

TORONTO–(BUSINESS WIRE)–GrowerIQ, a seed-to-sale technology and cannabis cultivation platform provider, is excited to announce a partnership with High North Labs. This partnership will improve the testing process for clients, with seamless, system-to-system integration of lab results transmitted automatically to GrowerIQ’s digital batch record. The tie-up also includes benefits exclusively for GrowerIQ clients, including discounted testing…

Walmart Sues DOJ and DEA Seeking Clarity for Pharmacists in Dispensing Prescription Opioids

BENTONVILLE, Ark.–(BUSINESS WIRE)–Walmart has sued the U.S. Department of Justice (DOJ) and the Drug Enforcement Administration (DEA), asking a federal court to clarify the roles and responsibilities of pharmacists and pharmacies under the Controlled Substances Act (CSA). Walmart Inc. v. DOJ, et al. is pending before the U.S. District Court for the Eastern District of…

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced for the first time results from its Phase 1 clinical trial evaluating GFB-887, a first-in-class highly potent and selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), in healthy volunteers.…

Sproutly Amends Maturity Date of Private Debt

VANCOUVER, British Columbia–(BUSINESS WIRE)–Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (“Sproutly” or the “Company”) announced today that the Company and Infusion Biosciences Inc. (“Infusion”) have entered into agreements to extend the maturity dates of both the $1 million private loan issued by Infusion to the Company on January 28, 2020 (the “January Infusion…

Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ILLUMINATE-B Phase 3 pediatric study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of…